INV4
1月前
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on May 1, 2026, the company granted a non-statutory stock option to purchase an aggregate of 276,200 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option award has an exercise price of $4.92 per share, the closing price of Absci’s common stock on the Nasdaq Global Select Market on May 1, 2026 the (“Grant Date”). The stock option has a 10-year term and vests over four years, and 25% of the shares subject to the option vest and become exercisable on the one-year anniversary of the Grant Date and the remaining 75% of the shares subject to the option vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to the new employee will be fully vested on the fourth anniversary of the Grant Date, subject to the new employee’s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com
Media Contact
press@absci.com
Link article
$ABSI 🗞️
Dharna
11月前
Short squeeze??? Looks good for one
Share Structure & Short Metrics
Outstanding shares: ~127.6?M
Float (public shares available): ~111.5?M StockAnalysis+11MarketBeat+11Seeking Alpha+11
Short interest: ~32.1?M shares, which is 28.8% of float (or ~25% of total shares) MarketBeat+1MarketBeat+1
Days to cover: ~9–10?days (varies by source: ~9.9 from MarketBeat, ~8.7 from StockAnalysis, ~6.7 from Fintel/Benzinga) Fintel+3MarketBeat+3Benzinga+3
Short interest trend: A ~23% increase in short interest in June, from ~26?M to ~32?M shares StockAnalysis+2MarketBeat+2Reddit+2
🔍 What This Means for a Possible Short Squeeze
A short squeeze is more likely when:
High short interest as percentage of float (=20%)
Elevated days to cover ratio (=5 days)
Catalysts like positive news or spikes in buying volume
ABSI checks the first two boxes:
Nearly 29% short float—substantially high
8–10 days to cover, indicating shorts would take a long time to unwind
Add in several bullish signals:
AI/ML-driven drug discovery partnerships (e.g., with AMD, Merck, AstraZeneca) Fintel+2Wikipedia+2Reddit+2MarketBeatBenzinga+3MarketBeat+3Fintel+3Wikipedia+5Reddit+5MarketBeat+5Yahoo Finance+10Reddit+10MarketBeat+10
Recent analyst upgrades (Needham, HC Wainwright, Guggenheim) with $7–$10 price targets MarketBeat
If ABSI experiences a strong positive catalyst or sharp price uptrend, the short sellers could be forced to scramble, buying to cover—a textbook setup for a short squeeze.
⚠️ Considerations & Risks
Volatile stock (high beta ~2.0–2.5)—price moves can be exaggerated Reddit+13Fintel+13Newser+13
A squeeze isn't guaranteed—market momentum and broader investor sentiment heavily influence outcomes
Catalyst-dependent—without a strong spark (earnings beat, major partnership, or takeover buzz), the squeeze may not materialize
✅ Bottom Line
ABSI has the classic technical setup for a short squeeze: very high short float, lengthy days to cover, and ongoing bullish interest. If positive news or a surge in buying pressure emerges, a squeeze could follow. But absent that catalyst, the stock may just meander or pull back, even though it's primed structurally.
Bandicoot_Inv
1年前
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
07:30:00 AM ET, 01/10/2025 - GlobeNewswire
VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics, today announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.
“At Absci, we’re constantly pushing the boundaries of innovation to bring better biologics to patients faster,” said Sean McClain, Founder and CEO of Absci. “By combining Absci’s AI de novo design expertise with Owkin’s world-class predictive AI target discovery technology, we have a unique opportunity to design first-in-class and potentially transformative therapeutics for patients in need.”
Through this strategic partnership, Absci and Owkin will co-develop therapeutic candidates addressing novel targets in immuno-oncology and other indications, such as immunology and inflammation. Owkin’s predictive AI models will optimize target selection and validate therapeutic hypotheses using extensive biomedical datasets and patient-derived organoids. Absci’s generative AI Drug Creation platform, including its de novo antibody design models, will rapidly design therapeutic candidates against these novel targets. Together, the companies will aim to streamline and accelerate the path from research to clinical development.
“At Owkin, our mission is to use patient data and Owkin K, our Operating System, to revolutionize drug discovery and development,” said Thomas Clozel, MD, CEO and Co-Founder of Owkin. “This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin’s AI agents that can identify and experimentally validate novel therapeutic targets with Absci’s pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.”
This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new partnership, Absci has added drug creation partnerships with four new Partners in 2024, achieving the Company's outlook for the year. Similarly, Owkin has established itself as a pioneer in predictive AI, working with top-tier pharmaceutical companies such as Sanofi and BMS to advance drug discovery and development as well as its differentiated pipeline of drug candidates and AI diagnostics
Bandicoot_Inv
1年前
ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer's disease.Absci Corporation (ABSI) announced a partnership bringing together two leading AI platforms to rapidly discover and design novel therapeutics for patients.Tourmaline Bio (TRML) announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board.
Monksdream
2年前
C
A prescription drug bottle filled with 0s and 1s to represent binary code.Francis Scialabba
CFOs are embracing AI, experimenting with new use cases for it throughout the finance function. But some CFOs are tapping the potential of the technology in other ways. At biotech firm Absci, researchers are using AI to develop drugs to treat cancer. (We’re not saying that to make your Claude-drafted emails look bad, we promise.)
Absci’s CFO and CBO, Zach Jonasson, spoke with CFO Brew about how AI is allowing the company to create and test new antibodies faster—and cheaper—than ever before.
Absci uses E. coli—yes, the same bacteria that can give you some nasty infections—to manufacture antibodies that can be used in a variety of therapies. Using a process called “high throughput screening,” it then tests the antibodies, and it patents therapies containing the most promising ones.
Even before ChatGPT burst onto the scene, Absci saw potential in AI. Through its testing of antibodies, the company generated large amounts of data, which it realized could be used to train an AI. In 2021, it acquired a deep learning company called Denovium, which became “the nucleus” that it built a proprietary AI around, Jonasson said.
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
TrendTrade2016
16時間前
MisterBet
11月前
メールアドレスで登録
